This Week In OHDSI

July 16, 2024

The July 16 (11 am ET) community call focused on the HowOften Initiative, including early findings following the 2023 OHDSI Global Symposium workshop, different projects using HowOften, including one related to clinicaltrials.gov data, and future steps. Below are the leads for the different talks; slides and videos from the session are located below.

• Hsin Yi “Cindy” Chen (MD-PhD Student, Columbia University Department of Biomedical Informatics)
• Azza Shoaibi (Director, Observational Health Data Analytics, Janssen Research and Development)
• Elise Ruan (Clinical Informatics Fellow, NewYork-Presbyterian Hospital/Columbia University)
• George Hripcsak (Professor of Biomedical Informatics, Columbia University)

Community Updates

• Congratulations to the team of Jason Patterson and Nicholas Tatonetti on the publication of KG-LIME: predicting individualized risk of adverse drug events for multiple sclerosis disease-modifying therapy in JAMIA.

Congratulations to the team of Yong Shang, Yu Tian, Kewei Lyu, Tianshu Zhou, Ping Zhang, Jianghua Chen, and Jingsong Li on the publication of Electronic Health Record–Oriented Knowledge Graph System for Collaborative Clinical Decision Support Using Multicenter Fragmented Medical Data: Design and Application Study in the Journal of Medical Internet Research.

• The Eye Care & Vision Research workgroup is leading a Semaglutide NAION network study based on last week’s OHDSI Evidence Network presentation. Cindy Cai and Michelle Hribar discussed this study and the value of network collaboration; please use this link to join the Eye Care & Vision Workgroup.

• The next CBER BEST Seminar will be held Wed., July 17, at 11 am ET and will be led by Yonas Ghebremichael-Weldeselassie, Lecturer of Statistics at School of Mathematics and Statistics, The Open University, UK. The focus of this talk will be A modified self-controlled case series method for event-dependent exposures and high event-related mortality, with application to COVID-19 vaccine safety. You can access the session using this link.

The fifth European OHDSI Symposium, titled “Scaling up Reliable Evidence Across Europe,” was held June 1-3 and brought together data partners, regulators, and researchers to collaborate and share results and ideas about the use of the OMOP-CDM in Europe. All materials from the session, including talks focused on the Selection of European Initiatives Using the OMOP CDM and Large Scale Evidence Generation in EHDEN and DARWIN EU®, as well as the collaborator showcase, can be found all on the event homepage.

OHDSI Social Showcase

• Research from the 2024 Europe Symposium Collaborator Showcase is also being shared daily on OHDSI’s LinkedIn, Twitter/X and Instagram feeds as part of the #OHDSISocialShowcase. Below are posters (with study leads) that are featured this week:

Monday — Advancing Certification and Evaluation of Medical Device Software in the EU using OMOP (Frédéric Jung)
Tuesday — SNOMED overhaul and its impact on ETL and phenotyping (Masha Khitrun)
Wednesday — OMOPification of real world cancer data to enable privacy-preserving analytics for cancer research (Prabash Galgane Banduge)
Thursday — The association between comorbid depression and insulin initiation in type 2 diabetes A cohort OHDSI study (Christianus Heru Setiawan)
Friday — Empowering research with seamless data flow and research-ready, anonymised data in OMOP CDM: Learnings from the design of WAYFIND-R, a global precision oncology registry and research platform (Tom Stone)

2024 OHDSI Global Symposium

Registration is open for the 2024 Global Symposium, which will be held Oct. 22-24 at the Hyatt Regency Hotel in New Brunswick, N.J., USA. The three-day event will feature tutorials on Day 1, plenaries and the collaborator showcase on Day 2, and workgroup activities on Day 3.

• Day 1 will open with a single tutorial in the morning: An Introduction to the Journey from Data to Evidence using OHDSI. There will be four advanced tutorials during the afternoon: An Introduction to the Journey from Data to Evidence using OHDSI; Developing and Evaluating Your Extract, Transform, Load (ETL) Process to the OMOP Common Data Model; So, You Think You Want To Run an OHDSI Network Study?; and Using the OHDSI Standardized Vocabularies for Research. You can select your tutorials during the registration process.

Job Openings

Ross Williams announced an opening for a Health Data Scientist at Erasmus MC. The candidate will be responsible for the creation and execution of study software to support the work of epidemiologists. This will include designing, developing, documenting, and maintaining R code that will be executed against health data that is standardized to the OMOP Common Data Model. More information and an application link are available here.

• Ajit Londhe announced an opening for a Senior Associate Director, Real World Evidence and Analytics at Boehringer Ingelheim. The candidate for this remote position will have the opportunity to generate real world evidence (RWE) to support in-line and pipeline products, provide statistical advice on the analysis of real world data (RWD) to various internal and external stakeholders, contribute to the RWD acquisition strategy and tool evaluation, and participate in the development and presentation of RWE trainings. More information and an application link is available here.

• Kevin Haynes shared an opening at CVS Health for a Lead Director, RWE Distributed Research. This position will lead a team of Analytic professionals responsible for transformation of healthcare insurance and pharmacy data into distributed analytic models, including OMOP, used in safety surveillance and collaborative research (SS&C). More information and an application link is available here.

• Aki Nishimura announced that Johns Hopkins University is seeking postdoctoral fellows. The fellows would work on methodological research in pharmaco-epidemiology to address medication and device utilization, effectiveness, and safety relevant to health, lung, and blood diseases. More information and application details are available here. If you are interested in having Aki Nishimura as a co-advisor, please include him on your application email at aki.nishimura@jhu.edu.

Slides

HowOften: Background | Trends in Hospitalization Among Patients with Cardiovascular, Immunological, and neurological Illnesses | Does Indication Matter? | Standardization of Clinical Trials Data for Large-Scale Incidence Calculations of Adverse Drug Events | Future Steps

Community Updates

Video Presentation

00:40 – Background (Chen)
04:22 – Trends in Hospitalization Among Patients with Cardiovascular, Immunological, and neurological Illnesses (Shoaibi)
15:58 – Does Indication Matter? (Chen)
25:56 – Standardization of Clinical Trials Data for Large-Scale Incidence Calculations of Adverse Drug Events (Ruan)
40:28 – Future Steps (Hripcsak)